ArticleOncology and therapy2025

A Cost-Effectiveness Analysis for Avelumab as a First-Line Maintenance Treatment of Advanced Urothelial Carcinoma in the Netherlands.

David Smalbrugge et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.